Additionally, to investigate whether Lyc.HCL exerts its antitumor effect on ESCC cells by targeting TRIM22, we constructed transient cell models of TRIM22 overexpression and knockdown that were then treated with Lyc.HCL. This evidence concerns the gene TRIM22 and esophageal squamous cell carcinoma.